Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandro Barni

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
Medical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro Barni
Translational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro Barni
Breast Cancer Research and Treatment|November 24, 2021
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx studySandro Barni, Francesco Cognetti, Fausto Petrelli
Expert Review of Anticancer Therapy|November 5, 2015
Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agentsAndrea Coinu, Fausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|April 26, 2011
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trialsFausto Petrelli, Mary Cabiddu, Sandro Barni
Clinical Breast Cancer|December 31, 2022
Lobular Carcinoma of the Breast and Utility of Oncotype Dx®: a Retrospective Decision Impact AnalysisSandro Barni, Alessandra Fabi, Fausto Petrelli
Critical Reviews in Oncology/Hematology|May 5, 2016
Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the artSandro Barni, Fausto Petrelli, Mary Cabiddu
European Journal of Cancer (Oxford, England : 1990)|March 7, 2017
Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancersFausto Petrelli, Gianluca Tomasello, Sandro Barni
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
Medical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro Barni
Translational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro Barni
Breast Cancer Research and Treatment|November 24, 2021
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx studySandro Barni, Francesco Cognetti, Fausto Petrelli
Expert Review of Anticancer Therapy|November 5, 2015
Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agentsAndrea Coinu, Fausto Petrelli, Sandro Barni
Medical Oncology (Northwood, London, England)|April 26, 2011
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trialsFausto Petrelli, Mary Cabiddu, Sandro Barni
Clinical Breast Cancer|December 31, 2022
Lobular Carcinoma of the Breast and Utility of Oncotype Dx®: a Retrospective Decision Impact AnalysisSandro Barni, Alessandra Fabi, Fausto Petrelli
Critical Reviews in Oncology/Hematology|May 5, 2016
Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the artSandro Barni, Fausto Petrelli, Mary Cabiddu
European Journal of Cancer (Oxford, England : 1990)|March 7, 2017
Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancersFausto Petrelli, Gianluca Tomasello, Sandro Barni
Pageof 24